# EDGAR Filing Document

**Accession Number:** 0000355019
**File Stem:** 0001731122-25-000999
**Filing Date:** 2025-7
**Character Count:** 11000
**Document Hash:** d6bbf64c589de0ad8c9c73360b93bc74
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001731122-25-000999.hdr.sgml**: 20250721

**ACCESSION NUMBER**: 0001731122-25-000999

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250718

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20250721

**DATE AS OF CHANGE**: 20250721

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FONAR CORP
- **CENTRAL INDEX KEY:** 0000355019
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 112464137
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-10248
- **FILM NUMBER:** 251137050

**BUSINESS ADDRESS:**
- **STREET 1:** 110 MARCUS DR
- **CITY:** MELVILLE
- **STATE:** NY
- **ZIP:** 11747
- **BUSINESS PHONE:** 6316942929

**MAIL ADDRESS:**
- **STREET 1:** 110 MARCUS DRIVE
- **CITY:** MELVILLE
- **STATE:** NY
- **ZIP:** 11747

?xml version='1.0' encoding='ASCII'?

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Act of 1934

Date of Report (Date of earliest event reported): July 18, 2025

![](fonar_logo.jpg)

FONAR CORPORATION

------

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Delaware | &nbsp;&nbsp;0-10248 | &nbsp;&nbsp;11-2464137 |
| &nbsp;&nbsp;(State or other jurisdiction of incorporation) | &nbsp;&nbsp;(Commission File Number) | &nbsp;&nbsp;(I.R.S. Employer Identification No.) |
|  | &nbsp;&nbsp;110 Marcus Drive, Melville, New York 11747<br> (631) 694-2929 |  |
|  | &nbsp;&nbsp;(Address, including zip code, and telephone number of registrant's principal executive office) |  |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act 17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b) of the Act.

---

| | | |
|:---|:---|:---|
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
| Common Stock, $.0001 par value | FONR | Nasdaq Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01: Other Events

On July 18, 2025, FONAR Corporation. (the "Company") issued a press release announcing that the Special Committee of the Board of Directors had received a supplemental letter from the Proposed Acquisition Group led by Timothy Damadian, the Company's Chief Executive Officer, proposing a potential transaction in which the Group would acquire all of the Company's outstanding capital stock that it does not currently own for $17.25 per share in cash.

The press release is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

Exhibits:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[99.1 Press Release dated July 18, 2025.](fonar_exhibit-99.htm)

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| |
|:---|
| FONAR CORPORATION |
| (Registrant) |
| --------------------------------------------------------------- |
| By /s/ John P. Collins |
| John P. Collins |
| General Counsel |

---

Dated: July 21, 2025

## Ex-99

---

| | | |
|:---|:---|:---|
| NEWS | ![](fonar_logo.jpg) | Fonar Corporation |
| For Immediate Release | ![](fonar_logo.jpg) | The Inventor of MR Scanning™ |
| Contact: Daniel Culver | ![](fonar_logo.jpg) | An ISO 13485 Company |
| Director of Communications | ![](fonar_logo.jpg) | Melville, New York 11747 |
| E-mail: investor@fonar.com | ![](fonar_logo.jpg) | Phone: (631) 694-2929 |
| www.fonar.com | ![](fonar_logo.jpg) | Fax: (631) 390-1772 |

---

**SPECIAL COMMITTEE OF FONAR BOARD OF DIRECTORS <br> ANNOUNCES RECEIPT OF SUPPLEMENTAL "TAKE PRIVATE" PROPOSAL**

MELVILLE, NEW YORK, July 18, 2025 – The Special Committee of the Board of Directors of FONAR Corporation (NASDAQ-FONR) ("FONAR"), The Inventor of MR Scanning™, today confirmed receipt of a supplemental proposal letter, dated July 17, 2025, from the Proposed Acquisition Group led by Timothy Damadian. The supplemental letter states that the Proposed Acquisition Group is contemplating the pursuit of a plan to acquire all of the outstanding shares capital stock of FONAR not currently owned by the Proposed Acquisition Group, at a price of $17.25 per share in cash. The letter states that the proposed share price represents a premium of approximately 27% over the average closing price of the Common Stock for the 90 trading day trading period ending on June 30, 2025. A copy of the Proposed Acquisition Group's supplemental letter is attached as an exhibit to the Group's Amended Schedule 13D/A No.1, which is available for review by the public on the Securities and Exchange Commission's website.

The Special Committee, composed of independent and disinterested directors, was formed in response to interest expressed by the Proposed Acquisition Group in exploring a possible transaction in a letter delivered to the FONAR Board and dated July 7, 2025. The Special Committee will carefully review the supplemental proposal in consultation with independent financial and legal advisors to determine the course of action that is in the best interest of FONAR and all shareholders. No action is required by FONAR shareholders at this time.

FONAR cautions its shareholders and others considering trading in FONAR's securities that FONAR has only recently received the supplemental proposal letter and no decisions have been made with respect to FONAR's response to the proposed transaction. The proposal constitutes only an indication of interest by the Proposed Acquisition Group and does not constitute a binding commitment.

There can be no assurance that any agreement will be executed or that the transaction contemplated in the proposal or any other transaction will be approved or consummated. No agreement, arrangement or understanding between FONAR and the Proposed Acquisition Group relating to any proposed transaction will be created unless definitive documentation is executed and delivered by the appropriate parties.

FONAR does not anticipate making any further public statements about this matter or the activities of the Special Committee unless and until either it enters into a definitive agreement for a transaction or the Special Committee determines that no such transaction will be effected.

#

![](fonar_logo.jpg)

**About FONAR**

FONAR, The Inventor of MR Scanning™, located in Melville, NY, was incorporated in 1978, and is the first, oldest and most experienced MRI Company in the industry. FONAR went public in 1981 (Nasdaq:FONR). FONAR sold the world's first commercial MRI to Ronald J. Ross, MD, Cleveland, Ohio. It was installed in 1980. Dr. Ross and his team began the world's first clinical MRI trials in January 1981. The results were reported in the June 1981 edition of Radiology/Nuclear Medicine Magazine and the April 1982 peer-reviewed article in the Journal Radiology. The technique used for obtaining T1 and T2 values was the FONAR technique (Field fOcusing Nuclear mAgnetic Resonance), not the back projection technique. www.fonar.com/innovations-timeline.html.

FONAR's signature product is the FONAR UPRIGHT® Multi-Position™ MRI (also known as the STAND-UP® MRI), the only whole-body MRI that performs Position™ Imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR UPRIGHT® Multi-Position™ MRI often detects patient problems that other MRI scanners cannot because they are lie-down, "weightless-only" scanners. The patient-friendly UPRIGHT® MRI has a near-zero patient claustrophobic rejection rate. As a FONAR customer states, "If the patient is claustrophobic in this scanner, they'll be claustrophobic in my parking lot." Approximately 85% of patients are scanned sitting while watching TV.

FONAR has new works-in-progress technology for visualizing and quantifying the cerebral hydraulics of the central nervous system, the flow of cerebrospinal fluid (CSF), which circulates throughout the brain and vertebral column at the rate of 32 quarts per day. This imaging and quantifying of the dynamics of this vital life-sustaining physiology of the body's neurologic system has been made possible first by FONAR's introduction of the MRI and now by this latest works-in-progress method for quantifying CSF in all the normal positions of the body, particularly in its upright flow against gravity. Patients with whiplash or other neck injuries are among those who will benefit from this new understanding.

FONAR's primary source of income and growth is attributable to its wholly-owned diagnostic imaging management subsidiary, Health Management Company of America (HMCA) www.hmca.com.

FONAR's substantial list of patents includes recent patents for its technology enabling full weight-bearing MRI imaging of all the gravity sensitive regions of the human anatomy, especially the brain, extremities and spine. It includes its newest technology for measuring the Upright cerebral hydraulics of the cerebrospinal fluid (CSF) of the central nervous system. FONAR's UPRIGHT® Multi-Position™ MRI is the only scanner licensed under these patents.

#

UPRIGHT®, and STAND-UP® are registered trademarks. The Inventor of MR Scanning™, CSP™, MultiPosition™, UPRIGHT RADIOLOGY™, pMRI™, CFS Videography™, Dynamic™ and The Proof is in the Picture™, are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.